AbbVie held off on launch until it also got the green light from the European Commission for its portable Vyafuser pump device – developed in partnership with Phillips-Medisize – which came ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

but AbbVie held off on launch until it also got the green light from the European Commission for its Vyafuser pump device – developed in partnership with Phillips-Medisize – last November.

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

AbbVie (ABBV) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

(Bloomberg) -- AbbVie Inc.’s Chief Executive Officer Richard A. Gonzalez will retire after a colorful tenure that included the multibillion takeover of Botox-maker Allergan as he raced to wean ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, which it acquired through its acquisition of Cerevel Therapeutics last year.

US FDA approves expanded use of Lilly's bowel disease drug Healthcare & Pharmaceuticalscategory· January 16, 2025 AbbVie plans to "commit less capital" towards experimental medicines for ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Louis Navellier is a prominent American investor, author, and financial analyst ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...